Medcura’s proprietary biosurgical technology has repeatedly demonstrated the rapid arrest of difficult-to-control surgical bleeding with industry-best, and disruptive, economics in numerous challenging pre-clinical models. Our technology’s inherent versatility permits platform expansions into highly differentiated product solutions, best illustrated in our new surgical and consumer product applications.